EAM
LYEL icon

Erste Asset Management’s Lyell Immunopharma LYEL Stock Holding History

Erste Asset Management’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-2,700
Closed -$81.5K – 558
2024
Q3 		$81.5K Hold
2,700
– – ﹤0.01% 504
2024
Q2 		$74.5K Hold
2,700
– – ﹤0.01% 500
2024
Q1 		$110K Hold
2,700
– – ﹤0.01% 487
2023
Q4 		$114K Hold
2,700
– – ﹤0.01% 500
2023
Q3 		$84.8K Hold
2,700
– – ﹤0.01% 504
2023
Q2 		$169K Hold
2,700
– – ﹤0.01% 498
2023
Q1 		$116K Hold
2,700
– – ﹤0.01% 526
2022
Q4 		$178K Hold
2,700
– – ﹤0.01% 499
2022
Q3 		$400K Hold
2,700
– – 0.01% 441
2022
Q2 		$362K Hold
2,700
– – 0.01% 460
2022
Q1 		$289K Buy
+2,700
New +$327K 0.01% 485

Other funds holding LYEL

MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $202M AUM 2.79% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $362M AUM 386.37% 1-Year Est. Return
VP
venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

Erste Asset Management's LYEL Position: Q4 2024 in Review

Erste Asset Management sold out of Lyell Immunopharma (LYEL) in Q4 2024, closing a stake of 2,700 shares — an estimated $81.5K sold.

Erste Asset Management first reported a position in LYEL in Q1 2022 and held it in 11 quarters. The position peaked at $400K in Q3 2022. 105 funds tracked by Wall St. Rank hold LYEL as of Q4 2024.

  • Erste Asset Management reported no remaining Lyell Immunopharma position as of Q4 2024 after selling out during the quarter.
  • Erste Asset Management sold 2,700 Lyell Immunopharma shares in Q4 2024, an estimated $81.5K.
  • Erste Asset Management first reported a position in Lyell Immunopharma in Q1 2022 and held it in 11 quarters.
  • Erste Asset Management's Lyell Immunopharma position peaked at $400K in Q3 2022.
  • 105 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q4 2024.

Based on Erste Asset Management's 13F filing for Q4 2024, filed 10 Feb 2025.